Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 15, 2021 07:00 ET | Source: Arch Biopartners

Arch Biopartners Enters into Worldwide License Agreement with Telara Pharma to Re-Purpose Cilastatin for the Treatment and Prevention of Acute Kidney Injury

Arch Biopartners is a clinical stage company developing new drug candidates for treating organ damage caused by inflammationNovel Mechanism of Action - selective dipeptidase-1 (DPEP-1) antagonists...